Sandoz Canada A.I CyberSecurity Scoring
21/01/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Sandoz Canada in 2026.
No incidents recorded for Sandoz Canada in 2026.
No incidents recorded for Sandoz Canada in 2026.
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
Latest updates, reports, and threat intel affecting the global network.
Sandoz aims to market a semaglutide biosimilar in Canada as soon as it recieves regulatory approval. Image credit: Robert Barrie/GlobalData.
Generic drugmaker Sandoz expects unbranded versions of Novo Nordisk's blockbuster diabetes drug Ozempic to launch in Canada by the end of...
In an Oct. 16 Instagram post, the 'Bachelor' alum described a "gross" Air Canada seat with “chunks of food on the remote control [and]...
Sandoz Canada, a leader in affordable medicines, today announced the launch of PrSandoz® Sacubitril-Valsartan, a high-quality affordable...
Drugmaker Sandoz could offer unbranded weight-loss drugs at an up to 70 per cent discount to the branded versions in Canada when patents...
Sandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturerAgreement will secure a...
Jubbonti and Wyost are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients.
Sandoz Canada announced today the launch of Pr Sandoz ® Lisdexamfetamine, a generic equivalent of Vyvanse*, approved for the same indications.
The most notable commercial case this week is Actra Performers' Rights Society v Re:Sound et al with a concerned amount of $43,100,000.
The Admin Columns plugin for WordPress is vulnerable to PHP Object Injection leading to Remote Code Execution in versions up to and including 7.0.18. This is due to the use of `unserialize()` without an `allowed_classes` restriction in the `IdsToCollection::get_ids_from_string()` function, which processes attacker-controlled post meta values without proper validation. This makes it possible for authenticated attackers with Contributor-level access and above to inject a serialized PHP object into a post's custom meta field and trigger arbitrary code execution by exploiting a bundled POP gadget chain, resulting in remote code execution as the web server user.
The Alba Board plugin for WordPress is vulnerable to authorization bypass in all versions up to, and including, 2.1.3. This is due to the plugin not properly verifying that a user is authorized to perform an action. This makes it possible for authenticated attackers, with subscriber-level access and above, to access arbitrary private alba_card post data, including title, description, assignee, due date, tags, and comments, that is intended to be restricted to Administrators and Editors. The handler is registered via the wp_ajax_nopriv_ hook and its nonce is exposed to all site visitors through wp_localize_script on pages containing the [alba_board] shortcode, making this exploitable by unauthenticated users who can access any such page.
Internationalized Domain Names in Applications (IDNA) for Python provides support for Internationalized Domain Names in Applications (IDNA) and Unicode IDNA Compatibility Processing. In versions prior to 3.15, payloads such as `"\u0660" * N` or `"\u30fb" * N + "\u6f22"` utilize the `valid_contexto` function prior to length rejection, and for high values of `N` will take a long time to process. This is the same issue as CVE-2024-3651, however the original remediation in 2024 was not a complete fix. A specially crafted argument to the `idna.encode()` function could consume significant resources. This may lead to a denial-of-service. Starting in version 3.14, the function rejects long inputs as soon as practicable prior to any further processing to minimize resource consumption. In version 3.15, this approach was extended to lesser used alternate functions (i.e. per-label conversions and codec support). A workaround is available. Domain names cannot exceed 253 characters in length. If this length limit is enforced prior to passing the domain to the `idna.encode()` function, it should no longer consume significant resources. This is triggered by arbitrarily large inputs that would not occur in normal usage, but may be passed to the library assuming there is no preliminary input validation by the higher-level application.
A path traversal vulnerability exists in the Projects Service download endpoint shared by Altium Enterprise Server and Altium 365. An authenticated user can supply a crafted path parameter that bypasses validation, allowing arbitrary files (including entire directories returned as archives) to be read from the server filesystem. Because the readable files include service configuration and credential material, exploitation can be used to gather information enabling further compromise. The issue can be combined with CVE-2026-11424 to reach the cloud-side endpoint. On multi-tenant Altium 365 deployments, the readable configuration could have exposed credentials shared across services. Altium Enterprise Server is fixed in 8.1.1; the issue has been remediated in Altium 365 at the service level.
A path traversal vulnerability exists in the Git Service component shared by Altium Enterprise Server and Altium 365. The service accepts a sequence of post-clone file-manipulation operations that use user-supplied paths without validation, allowing an authenticated user with basic git access to move arbitrary files outside the intended repository area. This file-move primitive can be used to place attacker-controlled script content into directories where it is later executed by the service, resulting in remote code execution under the Git Service account. On multi-tenant Altium 365 deployments, this could have allowed access to data belonging to other tenants on the same infrastructure node. Altium Enterprise Server is fixed in 8.1.1; the issue has been remediated in Altium 365 at the service level.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.